Metformin reverses tamoxifen resistance through the lncRNA GAS5-medicated mTOR pathway in breast cancer.

ABSTRACT:

Background

Metformin (Met) has antitumor effects on various cancers, but it is still unclear whether it exerts a reversible effect on endocrine resistance in breast cancer (BC) patients. In the present survey, metformin's effects on tamoxifen-resistant MCF cells (The cell line was established at the Michigan Cancer Foundation, hence the name MCF cell) were evaluated and the molecular mechanism was explored.

Methods

We constructed a tamoxifen-resistant BC cell line MCF-7R, then applied Cell Counting Kit-8 (CCK-8), flow cytometry, and EdU assessments to determine the growth and apoptosis of MCF-7R cells. Quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot were used to evaluate the expression level of lncRNA GAS5 and the mTOR-associated proteins. Overexp

SUBMITTER: Jiang Y 

PROVIDER: S-EPMC9011257 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature